ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1109

High Interleukin-13 Level Is Associated with Disease Stability in Interstitial Lung Disease

Elena Joerns1, David Karp1, Jeffrey Sparks2, Traci Adams1, Una Makris3 and Chad Newton1, 1UT Southwestern, Dallas, TX, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3UT Southwestern Medical Center and Dallas VA, Dallas, TX

Meeting: ACR Convergence 2022

Keywords: cytokines, interstitial lung disease, Miscellaneous Rheumatic and Inflammatory Diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: Miscellaneous Rheumatic and Inflammatory Diseases II

Session Type: Abstract Session

Session Time: 10:30AM-12:00PM

Background/Purpose: Interstitial lung disease (ILD) is a disease of lung parenchyma manifesting with inflammation and fibrosis. Interstitial lung disease (ILD) is a frequent complication of rheumatic diseases (RDs) but other types exist. Biomarkers can help differentiate between ILD subtype and predict prognosis. The objectives of our study were to 1) compare baseline cytokine levels between ILD subtypes, 2) evaluate baseline differences in cytokines between ILD patients exhibiting progressive phenotype and those without progression, and 3) evaluate differences between progressors and non-progressors within each ILD subtype.

Methods: We quantified 27 cytokines using Multiplex assay in peripheral blood samples from 234 patients with ILD (chronic hypersensitivity pneumonitis [cHP], RD-ILD, idiopathic pneumonia with autoimmune features [IPAF], idiopathic pulmonary fibrosis [IPF], and unclassifiable ILD [uILD]). Patients who were not on treatment (n=74) during sample collection were evaluated separately. Pairwise comparisons using Tukey method were performed to assess significant differences in cytokine levels between ILD subtypes. Multivariable logistic regression was performed to evaluate cytokine impact on the odds of progression. Student’s t-test was employed to evaluate differences in cytokine levels between progressors and non-progressors within each ILD subtype. As an exploratory analysis, multivariable logistic regression was utilized to evaluate cytokines predicting having an inflammatory ILD type (cHP and RD-ILD) as opposed to predominantly fibrotic (IPF) type.

Results: We found that baseline IL-17 level differed significantly between RD-ILD, IPF, and IPAF, being highest in RD-ILD and lowest in IPAF. Additionally, higher IL-13 level was strongly associated with increased odds of non-progression in our cohort (odds ratio 0.41, 95% confidence interval 0.20-0.85), with the levels being similar in non-progressors in all ILD types evaluated. FGF-b, GM-CSF, IL-12, and IL-17 were associated with greater odds of having inflammatory ILD type, rather than predominantly fibrotic type, even after adjusting for fibrosis severity and usual interstitial pneumonia radiographic pattern.

Conclusion: Investigations of biomarker differences between ILD subtypes is important, as accurate classification of ILD has clinical implications for treatment and management. IL-13 may be a useful biomarker predicting ILD stability. Further research is warranted to investigate cytokine levels within progressive and non-progressive ILD phenotypes with the goal of identifying biomarkers predicting progression and elucidating underlying pathogenesis. Future larger scale, prospective studies may help address both of these goals.

Supporting image 1

Figure 1: Mean IL_13 level comparison by progressor status for each ILD subtype, untreated patient cohort.
IL_13 – interleukin 13, ILD – interstitial lung disease, cHP – chronic hypersensitivity pneumonitis, IPAF – interstitial pneumonia with autoimmune features, IPF – idiopathic pulmonary fibrosis, RD-ILD – rheumatic disease associated ILD, uILD – unclassifiable ILD.

Supporting image 2

Figure 2. Cytokine level differences between ILD subtypes; (a) IL_17 level differs significantly between IPAF and RD-ILD and between RD-ILD and IPF in untreated cohort; (b) IL_17 differs significantly between IPAF and RD-ILD and IL_1-RA level differs significantly between IPAF and uILD in total cohort. [Log – natural log, IL – interleukin, cHP – chronic hypersensitivity pneumonitis, IPAF – interstitial pneumonia with autoimmune features, IPF – idiopathic pulmonary fibrosis, RD-ILD – rheumatic disease associated ILD, uILD – unclassifiable ILD].


Disclosures: E. Joerns, Pfizer, Inc; D. Karp, None; J. Sparks, Bristol Myers Squibb, AbbVie/Abbott, Amgen, Boehringer Ingelheim, Gilead, Inova Diagnostics, Janssen, Optum, Pfizer; T. Adams, None; U. Makris, None; C. Newton, Boehringer-Ingelheim.

To cite this abstract in AMA style:

Joerns E, Karp D, Sparks J, Adams T, Makris U, Newton C. High Interleukin-13 Level Is Associated with Disease Stability in Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/high-interleukin-13-level-is-associated-with-disease-stability-in-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-interleukin-13-level-is-associated-with-disease-stability-in-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology